Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Anastrozole - AstraZeneca

Drug Profile

Anastrozole - AstraZeneca

Alternative Names: Arimidex; ICI D 1033; ZD 1033

Latest Information Update: 20 May 2019

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator AstraZeneca
  • Class Antineoplastics; Nitriles; Small molecules; Triazoles
  • Mechanism of Action Aromatase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Breast cancer
  • Discontinued Female infertility

Most Recent Events

  • 01 Jun 2018 Efficacy data from phase III DATA trial presented at 54th Annual Meeting of the American Society of Clinical Oncology (ASCO-2018)
  • 14 Dec 2017 AstraZeneca suspends patient enrolment due to lack of accrual in a phase III trial in Breast cancer (Combination therapy, Metastatic disease, Second-line therapy or greater) in USA (PO) (NCT02137837)
  • 04 Nov 2017 No recent reports of development identified for phase-I development in Breast-cancer(In volunteers) in Japan (PO, Film)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top